Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing
- 942 Downloads
The study aimed to characterise the mechanism of release and absorption of Basmisanil, a biopharmaceutics classification system (BCS) class 2 compound, from immediate-release formulations via mechanistic absorption modelling, dissolution testing, and Raman imaging. An oral absorption model was developed in GastroPlus® and verified with single-dose pharmacokinetic data in humans. The properties and drug release behaviour of different oral Basmisanil formulations were characterised via biorelevant dissolution and Raman imaging studies. Finally, an in vitro-in vivo correlation (IVIVC) model was developed using conventional and mechanistic deconvolution methods for comparison. The GastroPlus model accurately simulated oral Basmisanil exposure from tablets and granules formulations containing micronized drug. Absorption of oral doses below 200 mg was mostly dissolution rate-limited and thus particularly sensitive to formulation properties. Indeed, reduced exposure was observed for a 120-mg film-coated tablet and the slower dissolution rate measured in biorelevant media was attributed to differences in drug load. This hypothesis was confirmed when Raman imaging showed that the percolation threshold was exceeded in this formulation. This biorelevant dissolution method clearly differentiated between the formulations and was used to develop a robust IVIVC model. The study demonstrates the applicability and impact of mechanistic absorption modelling and biopharmaceutical in vitro tools for rational drug development.
KEY WORDSabsorption modelling GastroPlus immediate-release formulation in vitro-in vivo correlation poorly water-soluble compound
The authors would like to thank Dr. Anni Pabst-Ravot (F. Hoffmann-La Roche Ltd., Basel, Switzerland) for analytical support. Dr. Carsten Brüsewitz (F. Hoffmann-La Roche Ltd., Basel, Switzerland) is gratefully acknowledged for providing the clinical study material for pharmacokinetic studies.
- 1.FDA. Guidance for Industry Q8(R2) Pharmaceutical Development. FDA (CDER). 2009.Google Scholar
- 2.Polli JE, Cook JA, Davit BM, Dickinson PA, Argenti D, Barbour N, et al. Summary workshop report: facilitating oral product development and reducing regulatory burden through novel approaches to assess bioavailability/bioequivalence. AAPS J. 2012;14(3):627–38. doi: 10.1208/s12248-012-9376-z.CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Kesisoglou F, Rossenu S, Farrell C, Van Den Heuvel M, Prohn M, Fitzpatrick S, et al. Development of in vitro-in vivo correlation for extended-release niacin after administration of hypromellose-based matrix formulations to healthy volunteers. J Pharm Sci. 2014;103(11):3713–23. doi: 10.1002/jps.24179.CrossRefPubMedGoogle Scholar
- 5.Ilic M, Duris J, Kovacevic I, Ibric S, Parojcic J. In vitro-in silico-in vivo drug absorption model development based on mechanistic gastrointestinal simulation and artificial neural networks: nifedipine osmotic release tablets case study. Eur J Pharm Sci. 2014;62:212–8. doi: 10.1016/j.ejps.2014.05.030.CrossRefPubMedGoogle Scholar
- 7.Selen A, Cruañes M, Müllertz A, Dickinson P, Cook J, Polli J, et al. Meeting report: applied biopharmaceutics and quality by design for dissolution/release specification setting: product quality for patient benefit. AAPS J. 2010;12(3):465–72. doi: 10.1208/s12248-010-9206-0.CrossRefPubMedPubMedCentralGoogle Scholar
- 11.Zhang H, Xia B, Sheng J, Heimbach T, Lin T-H, He H, et al. Application of physiologically based absorption modeling to formulation development of a low solubility, low permeability weak base: mechanistic investigation of food effect. AAPS PharmSciTech. 2014;15(2):400–6. doi: 10.1208/s12249-014-0075-1.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Potharaju S. Effect of compression force on agglomeration of micronized active pharmaceutical ingredients: techniques to prevent API agglomeration during compression. Tennessee: University of Tennessee Health Science Center; 2012.Google Scholar
- 23.Boersen N, Carvajal MT, Morris KR, Peck GE, Pinal R. The influence of API concentration on the roller compaction process: modeling and prediction of the post compacted ribbon, granule and tablet properties using multivariate data analysis. Drug Dev Ind Pharm. 2015;41(9):1470–8. doi: 10.3109/03639045.2014.958754.CrossRefPubMedGoogle Scholar
- 25.Honório da Silva T, Pinto EC, Rocha HVA, Esteves VSAD, dos Santos TC, Castro HCR, et al. In vitro–in vivo correlation of Efavirenz tablets using GastroPlus®. AAPS PharmSciTech. 2013;14(3):1244–54. doi: 10.1208/s12249-013-0016-4.